Holen Sie sich die Stockscreener-App
23.60
2.61%
0.60
Handel nachbörslich:
23.33
-0.27
-1.14%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$23.00
Offen:
$22.84
24-Stunden-Volumen:
3.64M
Relative Volume:
1.90
Marktkapitalisierung:
$2.28B
Einnahmen:
$610.16M
Nettoeinkommen (Verlust:
$-532.93M
KGV:
-4.2686
EPS:
-5.5287
Netto-Cashflow:
$-442.30M
1W Leistung:
-30.97%
1M Leistung:
-29.49%
6M Leistung:
-40.19%
1J Leistung:
-42.65%
1-Tages-Spanne:
$22.50
$24.00
1-Wochen-Bereich:
$18.41
$24.00
52-Wochen-Spanne:
$18.41
$46.50
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
23.60 | 2.22B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures - Genetic Engineering and Biotechnology News
ATTENTION RARE Shareholders: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Ultragenyx granted FDA priority review for gene therapy in rare brain disorder - MSN
Benzinga Bulls And Bears: Nike, SpaceX, Ultragenyx — And Chinese Tech Stocks Slide - Benzinga
ATTENTION Ultragenyx Pharmaceutical Inc. (RARE) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Ultragenyx stock eyes best day in 17 months as Wall Street shifts focus to 2026 pipeline after bone disease trial miss - MSN
Levi & Korsinsky Investigates Possible Securities Fraud by Ultragenyx Pharmaceutical Inc. (RARE) - ACCESS Newswire
Ultragenyx Phase III Data Reveal Limits of Bone Density Endpoints in Rare Bone Disease - BioPharm International
Bank of America Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00 - MarketBeat
Ultragenyx Pharmaceutical (RARE): B of A Securities Lowers Price Target | RARE Stock News - GuruFocus
Ultragenyx completes rolling submission of BLA for DTX401 - The Pharma Letter
Ultragenyx Pharmaceuticals Loses $1 Billion in Market Value After Bone Drug Fails Phase III Trials - geneonline.com
BofA Securities lowers Ultragenyx Pharma stock price target on failed trials By Investing.com - Investing.com South Africa
Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures - BioSpace
These nine Bay Area drug makers are hurtling toward key FDA approval decisions in 2026 - The Business Journals
BofA Securities lowers Ultragenyx Pharma stock price target on failed trials - Investing.com
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials - Fierce Biotech
Analysts Are Bullish on Top Healthcare Stocks: Tectonic Therapeutic (TECX), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials - Indian Pharma Post
RARE Rises on Completion of Rolling Submission for AAV Gene Therapy - The Globe and Mail
Lacklustre Performance Is Driving Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 32% Price Drop - 富途牛牛
Analysts’ Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Zevra Therapeutics (ZVRA) - The Globe and Mail
Ultragenyx recovers some losses as Jefferies sees potential 2026 rebound - MSN
Ultragenyx (RARE) Completes U.S. Application for Gene Therapy DT - GuruFocus
Ultragenyx completes rolling FDA submission for US approval of gene therapy - Seeking Alpha
Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus - ts2.tech
Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? - Yahoo Finance
Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall - Finviz
Ultragenyx (RARE) rockets 15.5% on bargain-hunting after steep fall - MSN
Why Ultragenyx Pharmaceuticals stock is plummeting today - MSN
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Why Did RARE Stock Plunge Over 41% Today? - Stocktwits
Shareholders Alert: Investigation Into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Ultragenyx completes BLA submission for GSDIa gene therapy By Investing.com - Investing.com Nigeria
Why Ultragenyx Pharmaceutical stock is bouncing back today - MSN
Ultragenyx Completes Rolling Submission of Biologics License Application for DTX401 Gene Therapy - marketscreener.com
Ultragenyx completes BLA filing for GSDIa gene therapy - TipRanks
Ultragenyx (RARE) Completes Key FDA Submission for Gene Therapy Approval - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx completes BLA submission for GSDIa gene therapy - Investing.com
Ultragenyx Pharmaceutical Sees Unusually Large Options Volume (NASDAQ:RARE) - MarketBeat
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) - The Globe and Mail
Ultragenyx Pharmaceutical Inc. Completes Rolling Submission of BLA for DTX401 Gene Therapy to Treat Glycogen Storage Disease Type Ia - Quiver Quantitative
Ultragenyx Pharmaceutical Completes BLA Submission for DTX401 - TradingView — Track All Markets
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today - AOL.com
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for ... - Caledonian Record
Ultragenyx Completes Rolling Submission of Biologics - GlobeNewswire
Why Ultragenyx stock dropped 42% and what comes next - MSN
Ultragenyx SVP Huizenga sells $2922 in shares By Investing.com - Investing.com Nigeria
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):